Article
Genetics & Heredity
Xiaotong Duan, Simiao Qiao, Dianhe Li, Shangbiao Li, Zhihao Zheng, Qin Wang, Xiaoxia Zhu
Summary: The combination of miR-492, miR-590-3p, and miR-631 can effectively distinguish healthy individuals from early-stage NSCLC patients, making them promising serum biomarkers for the early diagnosis of NSCLC.
FRONTIERS IN GENETICS
(2021)
Article
Oncology
Lang Xiong, Cheng Zhu, Yuhai Lu, Mao Chen, Mingwei Li
Summary: This study analyzed the levels of THBS2 in NSCLC patients' serum and evaluated its potential as a diagnostic biomarker for NSCLC. The results showed significantly elevated THBS2 levels in NSCLC patients and its correlation with clinicopathological characteristics. THBS2 exhibited superior diagnostic performance compared to traditional tumor markers, which could lead to improved patient outcomes.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Respiratory System
Xintong Zhang, Jinjing Tan, Yan Chen, Shang Ma, Wanqiu Bai, Yanjing Peng, Guangli Shi
Summary: Serum miRNAs miR-3149 and miR-4769.3p are up-regulated in NSCLC and may serve as potential biomarkers for early diagnosis of lung cancer when combined with tumor markers CEA and Cyfra21-1.
BMC PULMONARY MEDICINE
(2022)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Hailiang Ran, Jie Ma, Le Cai, Hai Zhou, Zhongqin Yuan, Ying Chen, Wei Chang, Yunchao Huang, Yuanyuan Xiao
Summary: This study found a significant association between serum cholinesterase (ChE) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients, with higher levels of ChE being related to better prognosis. Subgroup analysis revealed that the association between ChE levels and survival in NSCLC patients was more pronounced in specific circumstances.
Article
Chemistry, Multidisciplinary
Wenzhe Li, Ling Zhu, Kaidi Li, Siyuan Ye, Huayi Wang, Yadong Wang, Jianchao Xue, Chen Wang, Shanqing Li, Naixin Liang, Yanlian Yang
Summary: This study establishes a machine learning-assisted method for analyzing the expression of EGFR and CXCR4 in serum sEVs and demonstrates their potential as diagnostic and prognostic markers for NSCLC.
Article
Oncology
Giuseppe Giaccone, Yongfeng He
Summary: Lung cancer is the leading cause of cancer related death, with two major histological subtypes, NSCLC and SCLC. Transformation from NSCLC to SCLC can cause treatment resistance, potentially due to therapy-induced changes or clonal selection. This article discusses the potential mechanisms, cell of origin, and genomic alterations in both de novo and transformed SCLC, as well as treatment options including chemotherapy, radiotherapy, TKIs, immunotherapy, and antiangiogenic agents.
SEMINARS IN CANCER BIOLOGY
(2023)
Review
Oncology
Yan Wang, Xue Yang, Nan-Jing Li, Jian-Xin Xue
Summary: Leptomeningeal metastasis (LM) is a rare and highly fatal complication of non-small cell lung cancer (NSCLC). Improving the diagnosis and treatment of LM is crucial, as it severely affects patients' quality of life. Understanding the potential mechanisms of LM is helpful in addressing this issue. Clinical manifestations, magnetic resonance imaging, and CSF biopsy are key components in the diagnosis, and CSF cytology should be combined with liquid biology. Treatment options for LM patients include radiotherapy, intrathecal treatment, targeted therapy, and immunotherapy.
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Yimin Wang, Chuling Li, Zimu Wang, Zhaofeng Wang, Ranpu Wu, Ying Wu, Yong Song, Hongbing Liu
Summary: This systematic review evaluated the efficacy and safety of immunotherapy in early and late lung cancer, finding that immunotherapy has better efficacy in early lung cancer compared to advanced lung cancer, especially when combined with chemotherapy. In terms of safety, immunotherapy, either alone or in combination with other therapies, was found to be safer in early lung cancer than in advanced lung cancer.
Article
Multidisciplinary Sciences
Louisa Stern, Erik Mueller, Eugen Bellon, Matthias Reeh, Rainer Grotelueschen, Cenap Guengoer, Nathaniel Melling, Mara Goetz, Daniel R. Perez, Jakob R. Izbicki, Tamina Rawnaq-Moellers, Tarik Ghadban
Summary: S-MK is overexpressed in NSCLC patients and serves as an independent prognostic factor for overall survival. It may be considered as an additional non-invasive biomarker for both NSCLC screening and outcome prediction.
SCIENTIFIC REPORTS
(2021)
Review
Chemistry, Multidisciplinary
Piao Jiang, Bin Liang, Zhen Zhang, Bing Fan, Lin Zeng, Zhiyong Zhou, Zhifang Mao, Quan Xu, Weirong Yao, Qinglin Shen
Summary: Lung cancer is the most rapidly growing malignant tumor with the highest incidence and mortality rates, posing the greatest threat to human health and life. It is currently the leading malignant tumor in males and the second leading malignant tumor in females. In the era of precision medicine, there have been unprecedented changes in the concept and strategy of cancer diagnosis and treatment. Nanotechnology has brought new possibilities for tumor diagnosis and treatment, with nanomaterials playing an important role in tumor imaging, diagnosis, drug delivery, and controlled drug release. This article reviews the advancements in lipid-based nanosystems, polymer-based nanosystems, and inorganic nanosystems in the diagnosis and treatment of non-small-cell lung cancer (NSCLC).
Article
Multidisciplinary Sciences
Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G. Scott
Summary: In this study, the frequency-dependent interactions between a gefitinib-resistant non-small cell lung cancer population and its sensitive ancestor were measured experimentally. The cost of resistance was found to be insufficient in predicting competitive exclusion, and frequency-dependent growth rate measurements were necessary. Simulations showed that ecological growth effects can influence the predicted extinction time.
Review
Oncology
Alisa N. Blumenthaler, Mara B. Antonoff
Summary: Around half of NSCLC patients have metastatic disease at diagnosis, some with limited metastatic sites termed oligometastasis. Aggressive treatment of oligometastasis has shown improved survival rates, but the lack of a universal definition hinders comparison between studies.